Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay
The ability to identify non‐responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identifi...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 1999-08, Vol.106 (2), p.474-476 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 476 |
|---|---|
| container_issue | 2 |
| container_start_page | 474 |
| container_title | British journal of haematology |
| container_volume | 106 |
| creator | Bosanquet, Andrew G. Copplestone, J. Adrian Johnson, Stephen A. N. Smith, Alastair G. Povey, Sara J. Orchard, Jennifer A. Oscier, David G. |
| description | The ability to identify non‐responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine. |
| doi_str_mv | 10.1046/j.1365-2141.1999.01581.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69992290</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69992290</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4711-8dc86a19d9fafbcbfca6efb0628ef339574e2a14dcbd1971a7a4a9ecd484aec33</originalsourceid><addsrcrecordid>eNqNkd2O0zAQhS0EYsvCKyALIe5S7CRN4gsuoPwsaCUkfq6tiTOmLkmctZ1u8yy8LDatAHHFlUea7xzPzCGEcrbmrKye79e8qDZZzku-5kKINeObhq-Pd8jqd-MuWTHG6iwKmgvywPs9Y7xgG36fXCQTVrFmRX58Qj_Z0SMNlqoeOmdaMyI1I50cHoydfb_Q4BACdnSCYHAMnt6asKNq5-xoFO2XYdpZtYRU4_wdcDBATRdJo02UtQvFIz2Yg6XgPXo_xBa1mnZu_kY9jt4EczBhSeRr83mbMFgeknsaeo-Pzu8l-fr2zZftVXb98d377cvrTJU151nTqaYCLjqhQbeq1Qoq1C2r8gZ1UYhNXWIOvOxU23FRc6ihBIGqK5sSUBXFJXl28p2cvZnRBzkYr7DvYcS4v6zihfNcsAg--Qfc29mNcTbJRVPxPC9FhJoTpJz13qGWkzMDuEVyJtPh5V6mkGQKSab05K_05DFKH5_953bA7i_hKa4IPD0D4BX02sGojP_DiYrVdVroxQm7NT0u__2_fPXhKlXFT7QHuhg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198612249</pqid></control><display><type>article</type><title>Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Wiley Online Library All Journals</source><creator>Bosanquet, Andrew G. ; Copplestone, J. Adrian ; Johnson, Stephen A. N. ; Smith, Alastair G. ; Povey, Sara J. ; Orchard, Jennifer A. ; Oscier, David G.</creator><creatorcontrib>Bosanquet, Andrew G. ; Copplestone, J. Adrian ; Johnson, Stephen A. N. ; Smith, Alastair G. ; Povey, Sara J. ; Orchard, Jennifer A. ; Oscier, David G.</creatorcontrib><description>The ability to identify non‐responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1046/j.1365-2141.1999.01581.x</identifier><identifier>PMID: 10460608</identifier><identifier>CODEN: BJHEAL</identifier><language>eng</language><publisher>Oxford, U.K. and Cambridge, USA: Blackwell Science Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Chemotherapy ; cladribine ; Cladribine - therapeutic use ; differential staining cytotoxicity assay ; Drug Screening Assays, Antitumor ; Female ; Hematology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; phase II trial ; Recurrence ; Survival Analysis ; Treatment Outcome</subject><ispartof>British journal of haematology, 1999-08, Vol.106 (2), p.474-476</ispartof><rights>1999 INIST-CNRS</rights><rights>Copyright Blackwell Scientific Publications Ltd. Aug 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4711-8dc86a19d9fafbcbfca6efb0628ef339574e2a14dcbd1971a7a4a9ecd484aec33</citedby><cites>FETCH-LOGICAL-c4711-8dc86a19d9fafbcbfca6efb0628ef339574e2a14dcbd1971a7a4a9ecd484aec33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1365-2141.1999.01581.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1365-2141.1999.01581.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1960773$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10460608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bosanquet, Andrew G.</creatorcontrib><creatorcontrib>Copplestone, J. Adrian</creatorcontrib><creatorcontrib>Johnson, Stephen A. N.</creatorcontrib><creatorcontrib>Smith, Alastair G.</creatorcontrib><creatorcontrib>Povey, Sara J.</creatorcontrib><creatorcontrib>Orchard, Jennifer A.</creatorcontrib><creatorcontrib>Oscier, David G.</creatorcontrib><title>Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>The ability to identify non‐responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>cladribine</subject><subject>Cladribine - therapeutic use</subject><subject>differential staining cytotoxicity assay</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>phase II trial</subject><subject>Recurrence</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkd2O0zAQhS0EYsvCKyALIe5S7CRN4gsuoPwsaCUkfq6tiTOmLkmctZ1u8yy8LDatAHHFlUea7xzPzCGEcrbmrKye79e8qDZZzku-5kKINeObhq-Pd8jqd-MuWTHG6iwKmgvywPs9Y7xgG36fXCQTVrFmRX58Qj_Z0SMNlqoeOmdaMyI1I50cHoydfb_Q4BACdnSCYHAMnt6asKNq5-xoFO2XYdpZtYRU4_wdcDBATRdJo02UtQvFIz2Yg6XgPXo_xBa1mnZu_kY9jt4EczBhSeRr83mbMFgeknsaeo-Pzu8l-fr2zZftVXb98d377cvrTJU151nTqaYCLjqhQbeq1Qoq1C2r8gZ1UYhNXWIOvOxU23FRc6ihBIGqK5sSUBXFJXl28p2cvZnRBzkYr7DvYcS4v6zihfNcsAg--Qfc29mNcTbJRVPxPC9FhJoTpJz13qGWkzMDuEVyJtPh5V6mkGQKSab05K_05DFKH5_953bA7i_hKa4IPD0D4BX02sGojP_DiYrVdVroxQm7NT0u__2_fPXhKlXFT7QHuhg</recordid><startdate>199908</startdate><enddate>199908</enddate><creator>Bosanquet, Andrew G.</creator><creator>Copplestone, J. Adrian</creator><creator>Johnson, Stephen A. N.</creator><creator>Smith, Alastair G.</creator><creator>Povey, Sara J.</creator><creator>Orchard, Jennifer A.</creator><creator>Oscier, David G.</creator><general>Blackwell Science Ltd</general><general>Blackwell</general><general>Blackwell Publishing Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>199908</creationdate><title>Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay</title><author>Bosanquet, Andrew G. ; Copplestone, J. Adrian ; Johnson, Stephen A. N. ; Smith, Alastair G. ; Povey, Sara J. ; Orchard, Jennifer A. ; Oscier, David G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4711-8dc86a19d9fafbcbfca6efb0628ef339574e2a14dcbd1971a7a4a9ecd484aec33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>cladribine</topic><topic>Cladribine - therapeutic use</topic><topic>differential staining cytotoxicity assay</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>phase II trial</topic><topic>Recurrence</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bosanquet, Andrew G.</creatorcontrib><creatorcontrib>Copplestone, J. Adrian</creatorcontrib><creatorcontrib>Johnson, Stephen A. N.</creatorcontrib><creatorcontrib>Smith, Alastair G.</creatorcontrib><creatorcontrib>Povey, Sara J.</creatorcontrib><creatorcontrib>Orchard, Jennifer A.</creatorcontrib><creatorcontrib>Oscier, David G.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bosanquet, Andrew G.</au><au>Copplestone, J. Adrian</au><au>Johnson, Stephen A. N.</au><au>Smith, Alastair G.</au><au>Povey, Sara J.</au><au>Orchard, Jennifer A.</au><au>Oscier, David G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>1999-08</date><risdate>1999</risdate><volume>106</volume><issue>2</issue><spage>474</spage><epage>476</epage><pages>474-476</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><coden>BJHEAL</coden><abstract>The ability to identify non‐responders to cytotoxic chemotherapy has significant clinical and economic benefits. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identified as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1.5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine.</abstract><cop>Oxford, U.K. and Cambridge, USA</cop><pub>Blackwell Science Ltd</pub><pmid>10460608</pmid><doi>10.1046/j.1365-2141.1999.01581.x</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 1999-08, Vol.106 (2), p.474-476 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69992290 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Wiley Online Library All Journals |
| subjects | Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy cladribine Cladribine - therapeutic use differential staining cytotoxicity assay Drug Screening Assays, Antitumor Female Hematology Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments phase II trial Recurrence Survival Analysis Treatment Outcome |
| title | Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T18%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Response%20to%20cladribine%20in%20previously%20treated%20patients%20with%20chronic%20lymphocytic%20leukaemia%20identified%20by%20ex%20vivo%20assessment%20of%20drug%20sensitivity%20by%20DiSC%20assay&rft.jtitle=British%20journal%20of%20haematology&rft.au=Bosanquet,%20Andrew%20G.&rft.date=1999-08&rft.volume=106&rft.issue=2&rft.spage=474&rft.epage=476&rft.pages=474-476&rft.issn=0007-1048&rft.eissn=1365-2141&rft.coden=BJHEAL&rft_id=info:doi/10.1046/j.1365-2141.1999.01581.x&rft_dat=%3Cproquest_cross%3E69992290%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198612249&rft_id=info:pmid/10460608&rfr_iscdi=true |